Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Endless Endeavor with Greg Anderson

EE 086: Understanding Stem Cell, Exosome, and Growth Factor Treatments with Dr. Andrew Doe

10 Feb 2022

Description

In Episode 86, I sit down with Dr. Andrew Doe who owns and operates Alate Health in Houston, Texas. I flew down and had a treatment done to my knees that will regenerate cartilage with the hopes of lessening the pain and increasing the functionality of my knees. Dr. Doe goes into detail regarding my specific treatment and talks about all the different aspects of stem cell, exosomes, and growth factor treatments. This was an incredible podcast because Dr. Doe is not only a physician, but a veteran and a blackbelt in jiu jitsu, so we had no shortage of things to talk about. Many of our listeners are athletes, first responders, and soldiers, and we put our body through the wringer, so be prepared to take copious notes! Please enjoy episode 86 of the Endless Endeavor Podcast. --- Connect with me Instagram: @granderson33 Website: www.theelectricnorth.com for podcast apparel and gear Email: [email protected] Linktr.ee: https://linktr.ee/Granderson33 Connect with Dr. Andrew Doe Website: www.alatehealth.com Instagram: @andrewldoe_md Email: [email protected] Episode resources: Bio Pro + https://bioproteintech.com/product/biopro-plus coupon code ENDLESS saves $30 Moya Brand https://www.moyabrand.com Coupon ENDLESS 20% off Cured Nutrition https://www.curednutrition.com coupon ENDLESS 10% Off If you enjoy the show, make sure to give the Endless Endeavor Podcast a rating via your favorite audio platform OR on YouTube here: https://www.youtube.com/channel/UCieFsr26t9cyPDKMbLQJzXw/featured!

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.